Since defective variant alleles of both CYP2C9 and CYP2C19 occur at a lower frequency in the black African population, larger sample size studies are needed to explore further the impact of genetic variation on schistosomiasis treatment outcome in the sub-Sharan Africa population. This evidence concerns the gene CYP2C9 and schistosomiasis.